Cite
HARVARD Citation
Haratake, N. et al. (2019). Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients. Thoracic cancer. 10 (9), pp. 1779-1787. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Haratake, N. et al. (2019). Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients. Thoracic cancer. 10 (9), pp. 1779-1787. [Online].